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Abstract
As hyperlipidemia, including hypercholesterolemia (HC) and hypertriglyceridemia (HTN), continue to challenge
North America’s healthcare systems, patients continue to seek efficacious and safe natural therapies that comple-
ment pharmaceutical interventions. However, despite the ever-growing body of research supporting the use of
functional foods and nutraceuticals (FFN) for the prevention and treatment of hyperlipidemia, reception amongst
the medical community regarding the implementation of FFN into clinical guidelines continues to lag. Research
demonstrates that specific FFN target and modulate molecular processes that perpetuate hyperlipidemia. In addi-
tion, studies consistently demonstrate that combining certain FFN such as marine-derived omega-3 fatty acids or
plant sterols/stanols with statins enhances triglyceride and cholesterol-lowering efficacy, respectively. Thus, the
purpose of this commentary is to contend that efficacious FFN not only reduce HC and HTG but also boost the
lipid-lowering effects of pharmaceutical hypolipidemic medications. Finally, this editorial aims to challenge current
medical guidelines to emphasize efficacious FFN during all stages of treatment of hyperlipidemias as adjuncts to
pharmacotherapy.
Introduction
Hyperlipidemia, including hypercholesterolemia (HC)
and hypertriglyceridemia (HTG), remains a formative
burden on the health care systems of North America.
Given that a third of American adults meet the criteria
for metabolic syndrome [1], recent studies suggest extra-
ordinarily high prevalence rates of HC and HTG
amongst metabolic syndrome patients at 69 and 65%,
respectively [2]. In addition, hyperlipidemias are risk fac-
tors for vascular disease such as atherosclerosis [3,4].
Lifestyle interventions including diet, exercise and
weight loss are primary strategies during the initial
stages of treatment of HC and HTG [3,5]. However, if
lifestyle strategies are ineffective and/or patients begin
to exhibit multiple risk factors for chronic disease,
healthcare practitioners turn to lipid-lowering pharma-
ceuticals [5,6]. That being said, functional foods
and nutraceuticals (FFN) represent a growing genre
of therapies which have demonstrated efficacy for
hyperlipidemia when administered alone or in combina-
tion with pharmaceutical treatments. Nonetheless, the
question remains, where should FFN be positioned in
current guidelines as treatments for HC and HTG?
Over the last decade, considerable focus amongst the
research community has been directed toward enhan-
cing our understanding of FFN as therapies for lifestyle-
related diseases. As the severity of symptoms worsen
and patients advance through various stages of treat-
ment, prescription medications become the primary
therapeutic strategy, discounting FFN as disease-thwarting
agents. Hypercholesterolemia, characterized by escalat-
ing LDL-C levels, is a good example. The National
Cholesterol Education Program (NCEP) describes the
use of plant sterols/stanols (PS) as a therapeutic option
to physicians for reducing circulating LDL-C levels.
Despite the plethora of peer-reviewed articles demon-
strating consistent reductions in LDL-C with PS use,
t h eN C E Pd o e sn o ti n c l u d eP Sf o r t i f i e df o o d sa sa
constituent of the Therapeutic Lifestyle Diet, nor are
PS emphasized during the latter stages of therapy
when pharmaceuticals have been introduced to treat-
ment regimens [5]. Similarly, marine derived omega-3
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have all been shown to significantly reduce clinical
endpoints associated with HTG and HC and as with
PS, have not been adopted into treatment regimens
either. In addition, research demonstrates that thera-
peutic FFN, such as PS and MOM-3, can complement
pharmaceutical treatments, producing better clinical
outcomes than pharmaco-mono-therapy [7].
Functional foods and nutraceuticals are not merely
lifestyle interventions. Similar to pharmaceutical agents,
FFN contain bioactive substances that, when adminis-
tered at therapeutic doses, target and modulate biologi-
cal processes that foster the development of disease
(Figure 1). Thus, the gap that currently exists between
FFN research and the medical community needs to be
closed such that FFN can be implemented into clinical
guidelines so that treatments for hyperlipidemia can be
optimized throughout all stages of therapy (Figure 2).
Clinical Efficacy of Functional Foods and Nutraceuticals
for Treating Hyperlipidemia
Functional foods house bioactive compounds that elicit
biological effects beyond that of providing nutrition.
Typically functional foods can be consumed as whole
foods or their bioactives can be extracted and added to
other foods or concentrated into tablets, capsules or
elixirs as nutraceuticals. The disease modulating effects
of FFN have been known for decades. Over 50 years of
Figure 1 Mechanisms by which plant sterols, marine-derived omega-3 fatty acids, and insoluble fibres decrease dyslipidemia. 1. Plant
sterols (PS) displace dietary cholesterol from mixed micelles. Absorbed PS activate liver X receptor (LXR), increasing the expression of ATP-
binding cassette G transporters (ABCG) which pump absorbed PS back into the intestinal lumen. 2. Marine-derived omega-3 fatty acids (MOM-3)
increase the expression of peroxisome proliferator-a (PPAR-a) and farnesol X receptor (FXR) while reducing the expression of hepatocyte
nuclear-4a (HNF-4a) and LXR. Altogether, modulation of transcription factors by MOM-3 increases triglyceride b-oxidation and expression of
lipoprotein lipase (LPL) alongside a decrease in triglyceride synthesis. 3. Short-chain fatty acids (SCFA) produced from colonic fermentation of
insoluble fibres decrease adipose lipolyisis, reducing circulating levels of non-esterified fatty acids (NEFA). Insoluble fibers have also been shown
to inhibit excessive body fat accumulation which is hypothesized to propagate the expression of hepatic forkhead transcription factor (Foxa2),
peroxisome proliferator-activated receptor (PPAR)-g coactivator b (Pgc-1b), and PPAR-a, increasing hepatic triglyceride b-oxidation.
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culating LDL-C levels up to 15% [8-10]. The positive
correlation between PS-derived LDL-C lowering efficacy
and baseline LDL-C levels [11] indicate that the ability
for PS to lower LDL-C actually improves as LDL-C
levels escalate. Thus, individuals demonstrating the
greatest risk of cardiovascular disease secondary to high
LDL-C levels benefit the most from PS therapy. In addi-
tion, prospective analysis of men at high risk for cardio-
vascular disease revealed that a high PS-to-cholesterol
ratio significantly reduced the relative hazard risk for
mortality at 0.51 (95% CI, 0.30-0.87) compared to those
with a low PS-to-cholesterol ratio [12].
Similar to PS, the triglyceride-lowering effects of
MOM-3 have been thoroughly researched [13,14]. Stu-
dies have consistently demonstrated that 2-4 g/d supple-
mental MOM-3 reduce circulating triglycerides up to
34% in hypertriglyceridemic patients [15]. The benefits
of MOM-3 supplementation have also translated into
reductions in hard endpoints. Results from the GISSI-
prevenzione study showed that four months of
supplemental MOM-3 at 1 g/d in myocardial infarct
patients demonstrated a 50% reduction in the risk of
mortality [16]. After 3.5 years, the overall risk of death
and cardiovascular-related death was decreased 20% and
30%, respectively [17]. Finally, a large clinical trial (n =
18 645) with patients randomized to receive 1.8 g/d
M O M - 3n o t e da2 0 %r e d u c t i o ni nm a j o rc o r o n a r y
events over 5 years [18]. Research demonstrates that
MOM-3 are not only potent triglyceride-lowering
agents, but also useful in reducing the risk of mortality.
Based on sound clinical research, effective dietary regi-
mens incorporating soy protein, dietary fiber, PS and
nuts have also been explored. When combined, consti-
tuents of this “Portfolio Diet” were shown to reduce
LDL-C levels to the same extent as statin therapy at
29% and 31%, respectively [19]. In addition to a 30%
reduction in LDL-C levels, subjects consuming the Port-
folio Diet demonstrated a decrease in small dense LDL
particles (sdLDL) [20], a risk factor for atherosclerosis
given their heightened susceptibility to oxidation and
ability to penetrate arteriole walls [21-23]. Moreover,
Figure 2 Functional foods and nutraceuticals (FFN) as adjuncts to pharmacotherapy for the treatment as hyperlipidemia. Part A is a
visual depiction of how current clinical guidelines de-emphasize the use of (FFN) as treatments for hyperlipidemia progress. Part B incorporates
the notion that FFN should be emphasized during all stages of treatment for hyperlipidemia.
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on sdLDL were compared, the main site for reductions
in circulating LDL-C levels for both strategies were
attributed to a decrease in cholesterol found in the
sdLDL subfraction at -0.69 mmol/L and -0.99 mmol/L,
respectively [24]. Overall, MOM-3, PS and the Portfolio
Diet highlight the medicinal potential of FFN as thera-
pies for combating HC, HTG and subsequent deteriora-
tion of vascular function.
Functional Foods and Nutraceuticals Target Biological
Processes that Modulate Clinical Endpoints
FFN differ from most traditional diet-based lifestyle
interventions because most dietary recommendations
involve the limiting of factors that promote the develop-
ment of hyperlipidemia such as saturated fat [5]. FFN
therapies on the other hand, assume a similar approach
to pharmaceutical therapies and involve the introduction
of bioactive compounds that target and positively modu-
late biological processes (Figure 1). For example,
fibrates, a category of common lipid-lowering medica-
tions, act as ligands for transcription factors, enhancing
peroxisome proliferator-activated receptor alpha (PPAR-
a) activity, while reducting hepatocyte nuclear-4a
(HNF-4a) activity. The result is an increase in lipopro-
tein lipase expression and fatty acid oxidation, alongside
a reduction in VLDL synthesis [25,26]. Supplemental
MOM-3 impose similar effects on triglyceride synthesis
and oxidation via modulation of PPAR-a and HNF-4a
expression. In addition, MOM-3 also increase and
decrease farnesol X receptor (FXR) and liver X receptor
(LXR) expression, respectively, causing a down regula-
tion in the expression of sterol-regulatory binding pro-
tein 1c (SREBP 1c) [27]. SREBP 1c up-regulates the
expression of genes involved in TG synthesis [28]. Over-
all, studies demonstrate that MOM-3 are similar to
common prescription medications in that they modulate
the biological processes that regulate TG metabolism.
Plant sterols’ cholesterol-lowering mechanism of
action is inhibition of dietary cholesterol absorption in
the small intestine by displacing exogenous cholesterol
from mixed micelles. Studies demonstrate that PS act as
agonists for LXR and subsequently increase the expres-
sion of ATP-binding cassette G (ABCG) transporters
within the epithelial membrane [29]. ABCG transporters
prevent excessive absorption of PS by pumping intracel-
lular PS from epithelial cells back into the intestinal
lumen [30]. A relatively small proportion of individuals
possess a genetic condition called sitosterolemia
whereby high levels of PS are absorbed and are athero-
genic. Thus, an evolutionary presence of PS within the
diet is suggested by the fact that PS facilitate their own
removal from the body, where high levels of PS are not
permitted to accumulate in the blood.
In addition to impaired glucose metabolism, insulin
resistance propagates dyslipidemia via increased de novo
lipogenesis and high levels of circulating VLDL and LDL
particles [31]. Typically, insulin resistance is linked to
obesity, fostering adipose lipolysis and increased levels
of circulating non-esterified fatty acids (NEFA). NEFA
induce insulin resistance by inhibiting intracellular sig-
naling processes downstream of insulin/insulin-receptor
interactions [32]. Dietary insoluble fibres have been
linked to reductions in insulin resistance [33,34].
Although mechanisms are not completely understood, it
is hypothesized that colonic fermentation of insoluble
fibre produces short-chain fatty acids (SCFA) which
subsequently reduce lipolysis and circulating NEFA [35].
Recently, Roberston et al. [36] demonstrated that 30 g/d
supplemental resistant starch, a type of insoluble fibre,
increased insulin sensitivity alongside SCFA uptake by
muscle and adipose, circulating levels of ghrelin and
expression of adipose lipoprotein lipase. A recent com-
parison of the metabolic effects of insoluble and soluble
fibre in mice revealed that, in addition to lower insulin
resistance, mice fed insoluble fibre demonstrated lower
body weight and fat mass despite no differences in
energy intake [37]. Expression of G-protein coupled
receptor 40 (GPR40) in adipose tissue was also lower in
mice fed insoluble fibre. Decreased expression of GPR40
has been linked to reduced obesity-induced insulin
secretion by pancreatic b-cells [38]. Finally, the present
study noted increased expression of transcription factors
that are associated with triglyceride beta oxidation
including hepatic forkhead transcription factor (Foxa2),
peroxisome proliferator-activated receptor (PPAR)-g
coactivator b (Pgc-1b), and PPAR-a [37]. The authors
attribute enhanced expression of transcription factors to
the effect of insoluble fibre on inhibiting excessive
weight gain and body fat accumulation. Increased lipid
oxidation was reflected in liver homogenates demon-
strating lowering triglyceride levels in mice fed insoluble
fibre compared to soluble fibre [37]. Research demon-
strates that insoluble fibres modulate hepatic and adi-
pose tissue metabolism, reducing insulin resistance as
well as processes that lead to diabetic dyslipidemia. FFN
need to be viewed as treatments that can profoundly
benefit hyperlipidemic-related disease outcomes.
Functional Foods and Nutraceuticals as Adjuncts to
Pharmaceutical Therapies
The purpose of this commentary is not to discourage
the use of pharmaceuticals. Such interventions are an
invaluable part of global healthcare systems. The present
aim is to emphasize that not only do specific FFN target
biological processes that propagate hyperlipidemia, but
that certain FFN can serve as beneficial adjunctive treat-
ments which enhance pharmacotherapy. Combining
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to reduce triglyceride and LDL-C levels by an additional
15% and 17%, respectively [39,40]. Moreover, PS/statin
treatments can lower LDL-C levels equivalent to a dou-
ble dose of statins (-39%) [41]. Comparing 40 mg/d sim-
vastatin to therapeutic lifestyle interventions that
combined MOM-3 and Chinese red yeast rice noted
similar reductions in LDL-C levels between groups at 39
and 42%, respectively [42]. However, subjects consuming
MOM-3 and red yeast rice also noted a 29% reduction
in triglyceride levels, an observation not demonstrated
with statins alone. We acknowledge that Chinese red
yeast rice is a natural source of lovastatin [43]. However,
the amount of Chinese red yeast rice-derived lovastatin
provided in the present study was only 10-15 mg/d, far
less than a therapeutic dose of prescription statin [42].
This suggests that PS alongside a low-dose of statin may
provide the same LDL-C-lowering efficacy as typical sta-
tin treatments minus the side-effects. Observations that
FFN/prescription therapies produce additive or synergis-
tic effects are encouraging. However, a need continues
to exist for pertinent developments in FFN research to
be openly communicated to healthcare practitioners so
that they may be implemented into current clinical
guidelines and utilized by physicians to treat
hyperlipidemia.
Future Directions for Incorporating Functional Foods and
Nutraceuticals into Hyperlipidemic Clinical Guidelines
Clearly, not every identified bioactive that elicits a bene-
ficial effect on blood lipid levels will be a candidate for
inclusion into medicinal treatment guidelines. Dosage,
reproducible efficacy, and especially safety, must be
thoroughly examined prior to their approval and imple-
mentation. However, FFN such as PS and MOM-3,
which together amount to a surplus of safety, efficacy
and mechanistic studies, need to be examined as suita-
ble candidates as late-stage adjuncts to prescription
medications as treatments for dyslipidemia. Moreover,
similar to medications, patients must be individually
assessed as to whether they would benefit from FFN/
prescription regimens. For example, patients diagnosed
with sitosterolemia, as described above, would obviously
not be suitable for PS therapy. Other strategies such as
the Portfolio Diet, which includes PS, could likely be
implemented into patients’ hypolipidemic treatment
regimens with minimal concern considering many com-
ponents of the Portfolio Diet such as soy proteins, fibre
and nuts are common dietary constituents. Increasing
the presence of FFN within clinical guidelines requires
systematic evaluation of candidate FFN and these pro-
cesses are beyond the scope of this commentary. None-
theless, the advent of combination FFN/prescription
therapies will require that physicians undergo additional
nutritional training and likely enhance dietitians’ role in
executing patient treatment regimens, especially when
whole foods are utilized as vehicles for administering FFN.
Conclusions
Despite clinical studies showing that therapeutic dosages
of FFN effectively target and modulate biological pro-
cesses that foster the development of hyperlipidemia,
FFN continue to be overshadowed by prescription medi-
c a t i o n sa sp a t i e n t sp r o g r e s st h r o u g hc o n s e c u t i v es t a g e s
of treatment. Research demonstrates that specific FFN
are efficacious adjuncts to pharmacotherapy for the
treatment of hyperlipidemia. Hence, it is imperative that
developments in FFN research are incorporated into
current clinical guidelines that are used for treating HC
and HTG. In the wake of current prevalence rates of
hyperlipidemia amongst people with metabolic syn-
drome FFN can serve as efficacious adjuncts to pharmo-
therapy during all stages of treatment.
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